AA Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Iodixanol (Primary) ; Iohexol (Primary) ; Iopromide (Primary) ; Ioversol (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Acronyms THYROPED
- Sponsors GE Healthcare
- 31 May 2019 Planned End Date changed from 1 Dec 2023 to 1 Feb 2025.
- 31 May 2019 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 31 May 2019 Planned initiation date changed from 1 Feb 2019 to 1 Nov 2019.